Workflow
【私募调研记录】呈瑞投资调研科兴制药、澜起科技
688008Montage Technology(688008) 证券之星·2025-04-15 00:07

Group 1: Key Insights on Companies - Cansino Biologics has a clear strategic pipeline for innovative drug development, shifting focus from fast-follow monoclonal antibodies to dual-target or tri-target antibodies from 2022 to 2023, and planning to introduce FIC tri-target antibodies starting in 2024 [1] - The company anticipates completing some business development collaborations for its pipeline by 2025, with a focus on overseas partnerships from PCC to IND stages [1] - The GB18 project aims to improve weight loss and enhance muscle and fat weight, with injections expected every 3-4 weeks, and is currently under IND review in both China and the US [1] - The GB12 project, utilizing AI technology in collaboration with Baidu, features a bispecific antibody targeting IL-4R and IL-31, with limited market competition [1] - Cansino's international sales revenue growth target is set at 200%-400%, leveraging its overseas commercialization platform for long-term business growth [1] Group 2: Key Insights on Industry Trends - Lattice Semiconductor is focusing on the development of computing hardware chips over the next 5-10 years, particularly in interconnect chips, benefiting from over 20 years of deep technical accumulation [2] - The demand for DDR5 memory interface chips is expected to surge due to trends in the AI industry, with MRCD/MDB chips anticipated to become preferred solutions for high-performance computing and AI applications [2] - The company is advancing its PCIe Switch chip development, leveraging its successful experience with PCIe Retimer chips, which are expected to see increased demand driven by AI server shipments and PCIe protocol iterations [2] - The market potential for CXL-related applications is significant, with the company planning to continue its R&D in memory interface chips, PCIe Retimer, and MXC chips [2] - The company has implemented a performance evaluation system for executives based on market capitalization, aligning management interests with shareholder interests [2]